Your browser is no longer supported. Please, upgrade your browser.
ACHN Achillion Pharmaceuticals, Inc. daily Stock Chart
Achillion Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.54 Insider Own0.10% Shs Outstand139.60M Perf Week-0.64%
Market Cap861.33M Forward P/E- EPS next Y-0.78 Insider Trans-50.77% Shs Float139.60M Perf Month-2.22%
Income-74.60M PEG- EPS next Q-0.16 Inst Own81.00% Short Float8.46% Perf Quarter49.03%
Sales- P/S- EPS this Y18.30% Inst Trans1.92% Short Ratio3.91 Perf Half Y113.49%
Book/sh1.56 P/B3.96 EPS next Y-34.50% ROA-29.10% Target Price6.30 Perf Year97.12%
Cash/sh1.10 P/C5.60 EPS next 5Y17.58% ROE-30.90% 52W Range1.29 - 6.46 Perf YTD288.05%
Dividend- P/FCF- EPS past 5Y4.10% ROI- 52W High-4.49% Beta1.61
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin- 52W Low378.29% ATR0.09
Employees56 Current Ratio9.00 Sales Q/Q- Oper. Margin- RSI (14)66.75 Volatility1.30% 1.21%
OptionableYes Debt/Eq0.00 EPS Q/Q-22.40% Profit Margin- Rel Volume0.45 Prev Close6.15
ShortableYes LT Debt/Eq0.00 EarningsNov 06 Payout- Avg Volume3.02M Price6.17
Recom3.00 SMA20-1.20% SMA5011.57% SMA20059.83% Volume1,358,546 Change0.33%
Oct-18-19Downgrade SVB Leerink Outperform → Mkt Perform $5 → $6.30
May-21-18Upgrade Barclays Underweight → Equal Weight $5
Feb-08-18Initiated B. Riley FBR, Inc. Neutral $3.50
Sep-12-17Reiterated Ladenburg Thalmann Buy $9 → $6.50
Aug-10-17Downgrade Robert W. Baird Outperform → Neutral $5
Aug-09-17Reiterated Chardan Capital Markets Neutral $5 → $4
May-18-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-02-17Initiated Ladenburg Thalmann Buy $10
Nov-04-16Upgrade Chardan Capital Markets Sell → Neutral $5
Sep-23-16Reiterated Chardan Capital Markets Sell $4 → $5
Sep-23-16Initiated Wedbush Outperform $13
Sep-15-16Initiated FBR & Co. Outperform $16
Jul-14-16Initiated Chardan Capital Markets Sell $4
Jul-07-16Upgrade JMP Securities Mkt Perform → Mkt Outperform
Feb-26-16Upgrade Robert W. Baird Neutral → Outperform $10
Feb-25-16Reiterated Maxim Group Buy $11 → $8
Sep-09-15Initiated Jefferies Hold
Aug-13-15Reiterated Maxim Group Buy $19 → $11
May-20-15Reiterated Leerink Partners Outperform $25 → $16
May-20-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-07-19 11:31AM  Why Is Achillion (ACHN) Down 2.8% Since Last Earnings Report? Zacks
Nov-29-19 11:30PM  Rigrodsky & Long, P.A. Files Class Action Suit Against Achillion Pharmaceuticals, Inc. GlobeNewswire
11:49AM  8 Stocks Paul Tudor Jones Continues To Buy
Nov-27-19 12:15PM  5 Stocks That Pushed Russell 2000 ETF Higher Zacks
Nov-22-19 10:42AM  Moore Kuehn, PLLC Encourages Investors of SRC Energy, Inc. (SRCI), Achillion Pharmaceuticals, Inc. (ACHN), and Arotech Corporation (ARTX) to Contact Firm PR Newswire
Nov-20-19 09:50AM  Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH Zacks
Nov-19-19 07:30AM  European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor GlobeNewswire
Nov-14-19 09:58AM  Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength Zacks
Nov-11-19 07:30AM  Achillion Announces Clearance of Investigational New Drug Application for ACH-5228 GlobeNewswire
Nov-08-19 08:00AM  Pharma Sector Tops in October: Best ETFs & Stocks Zacks
Nov-07-19 04:55PM  SHAREHOLDER ALERT: Monteverde & Associates PC Continues Legal Inquiry Regarding the Buyout ACCESSWIRE
09:00AM  Merger Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies Is Fair to Shareholders - CISN, ACHN, VSI ACCESSWIRE
07:30AM  Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-06-19 02:36PM  Here is What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN) Insider Monkey
01:35PM  INVESTOR ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding the Transaction ACCESSWIRE
10:45AM  SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders - AYR, WLH, ACHN ACCESSWIRE
09:07AM  Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting GlobeNewswire
Nov-05-19 02:35PM  STOCKHOLDER ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding Buyout ACCESSWIRE
Nov-04-19 04:04PM  Merger Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders LPT, CISN, IPHS, ACHN GlobeNewswire
02:55PM  Lifshitz & Miller LLP Announces Investigation of Achillion Pharmaceuticals, Inc., Anixter International Inc., Central European Media Enterprises Ltd., Digital Realty Trust, Inc., Fitbit, Inc., MutualFirst Financial, Inc., and Ra Pharmaceuticals Inc. PR Newswire
Nov-01-19 06:00PM  STOCKHOLDER ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding the Buy Out ACCESSWIRE
02:10PM  Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies Is Fair to Shareholders RARX, ACHN, IPHS, CISN GlobeNewswire
Oct-30-19 03:45PM  SHAREHOLDER ALERT: Monteverde & Associates PC Reminds Investors of the Following Investigation ACCESSWIRE
10:43AM  Healthcare ETFs Win in October: Here's Why Zacks
Oct-29-19 03:02PM  SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, ACHN, RARX Shareholders About Its Ongoing Investigations GlobeNewswire
Oct-28-19 12:30PM  MERGER ALERT ACHN, RARX, and IPHS: Levi & Korsinsky, LLP Notifies Investors of Investigations Concerning the Sale of these Companies GlobeNewswire
Oct-24-19 01:59PM  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Acquisitions GlobeNewswire
11:26AM  ACHILLION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Achillion Pharmaceuticals, Inc. - ACHN Business Wire
11:09AM  The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals Zacks
09:35AM  SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues To Investigate Whether The Sale Of These Companies Is Fair To Shareholders - CISN, IPHS, ACHN ACCESSWIRE
Oct-23-19 04:35PM  MERGER ALERT ACHN, JAG, and ROAN: Levi & Korsinsky, LLP Notifies Investors of Investigations Concerning the Sale of these Companies GlobeNewswire
02:00PM  ACHN, ROAN, VSI: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Merger ACCESSWIRE
11:26AM  Alexion (ALXN) Beats on Q3 Earnings, Lifts 2019 Guidance Zacks
10:10AM  Biotech ETFs Surge on a Flurry of Positive News Zacks
09:45AM  Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates Zacks
Oct-22-19 03:07PM  Merger Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders IPHS, ACHN, RARX, TSG GlobeNewswire
Oct-21-19 09:33AM  Alexion Gets FDA Approval for Label Expansion of Ultomiris Zacks
Oct-19-19 10:30AM  INVESTOR ALERT: Monteverde & Associates PC Is Investingating The Merger ACCESSWIRE
Oct-18-19 04:50PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc. PR Newswire
12:05PM  Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings? Zacks
12:00PM  SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues To Investigate Whether The Sale Of These Companies Is Fair To Shareholders - RARX, DOVA, ACHN ACCESSWIRE
07:04AM  Alexion to Buy Achillion for $930M, Strengthen PNH Franchise Zacks
Oct-17-19 12:22PM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on Behalf of Achillion Shareholders and Encourages Achillion Investors to Contact the Firm PR Newswire
07:39AM  The Daily Biotech Pulse: FDA Panel Backs Shionogi's Antibiotic, Hepion Surges On Data Publication, Innate Pharma IPO Benzinga
Oct-16-19 09:35PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Achillion Pharmaceuticals, Inc. (NASDAQ GS: ACHN) ACCESSWIRE +71.78%
03:05PM  Montco biotech firm sold for $930M, shares soar American City Business Journals
12:00PM  ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout ACCESSWIRE
11:43AM  Alexion makes $930M acquisition in bid to bolster blockbuster drug American City Business Journals
11:38AM  ACHILLION MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Achillion Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm ACHN GlobeNewswire
11:15AM  Achillion Pharmaceuticals Stock Soars on Deal to Be Acquired by Alexion
10:44AM  Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Achillion Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Alexion Pharmaceuticals, Inc. PR Newswire
08:50AM  Achillion (ACHN) Alert: Johnson Fistel Investigates Proposed Sale of Achillion Pharmaceuticals; Are Shareholders Getting a Fair Deal? PR Newswire
07:25AM  Alexion To Acquire Achillion Pharma For $930M Benzinga
07:15AM  Achillion Pharmaceuticals' stock rockets after Alexion Pharmaceuticals $930 million buyout deal MarketWatch
06:41AM  Drugmaker Alexion to buy biotech Achillion in $930 mln deal Reuters
06:30AM  Alexion to Acquire Achillion Business Wire
06:00AM  Alexion Pharmaceuticals to Acquire Achillion in $930 Million Deal
Sep-26-19 11:32AM  Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN Zacks
08:32AM  Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-25-19 07:21AM  [video]Achillion Pharma Stock Soars as New Drug Gets FDA Breakthrough Status
07:00AM  Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria GlobeNewswire
Sep-19-19 06:19AM  How Much Cash Is Left In The Bank For Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)? Simply Wall St.
Sep-07-19 09:30AM  Why Is Achillion (ACHN) Down 11.2% Since Last Earnings Report? Zacks
Aug-29-19 05:00PM  Achillion to Present at the Baird 2019 Global Healthcare Conference GlobeNewswire
Aug-09-19 08:24AM  Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil Zacks
Aug-08-19 07:30AM  Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire +8.56%
Jul-26-19 05:29PM  Why Achillion Pharmaceuticals Stock Flew Higher Again Today Motley Fool +18.02%
Jul-23-19 12:30PM  Why Achillion Pharmaceuticals Stock Is Soaring Again Today Motley Fool +28.88%
Jul-22-19 05:50PM  Why Luckin Coffee, Beyond Meat, and Achillion Pharmaceuticals Jumped Today Motley Fool +16.39%
03:41PM  Why Achillion Pharmaceuticals Stock Jumped Today Motley Fool
07:00AM  Achillions ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers GlobeNewswire
Jul-17-19 06:00AM  Achillion Pharmaceuticals ACHN- 2019 Top Picks' Mid-Year Update MoneyShow
Jul-10-19 09:23AM  Does Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Have A High Beta? Simply Wall St.
Jul-04-19 08:35AM  Alexion's Ultomiris Receives EU Approval for PNH in Adults Zacks
Jun-28-19 08:45AM  Alexion Receives FDA Approval for Label Expansion of Soliris Zacks
Jun-26-19 06:29PM  Heres What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN) Insider Monkey
Jun-21-19 11:05AM  Alexion's sBLA for Ultomiris Gets Priority Review From FDA Zacks
Jun-13-19 07:00AM  Achillion to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-10-19 07:00AM  Achillion Announces Upcoming Scientific Presentation at the 24th Congress of the European Hematology Association GlobeNewswire
Jun-08-19 09:30AM  Why Is Achillion (ACHN) Down 1.4% Since Last Earnings Report? Zacks
May-17-19 08:03AM  The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering Benzinga
07:00AM  Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting GlobeNewswire
May-14-19 06:00AM  Achillion Granted Twentieth Patent for Factor D Portfolio GlobeNewswire +7.66%
May-13-19 09:13AM  Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1 Zacks -5.84%
May-11-19 08:40AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs Benzinga
May-09-19 04:00PM  What You Need to Know About Achillion Pharmaceuticals' Q1 Update Motley Fool
10:19AM  Achillion: 1Q Earnings Snapshot Associated Press
06:00AM  Achillion Reports First Quarter 2019 Financial Results GlobeNewswire
May-02-19 06:00AM  Biotech Bets and a Goodbye from a Favorite Expert MoneyShow
Apr-06-19 09:30AM  Why Is Achillion (ACHN) Up 25.6% Since Last Earnings Report? Zacks
Apr-04-19 10:23AM  Achillion Meets Enrollment Target in Kidney Disease Studies Zacks
Apr-03-19 12:50PM  Why Achillion Pharmaceuticals Stock Is Jumping Today Motley Fool
06:00AM  Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy GlobeNewswire
Mar-28-19 04:41PM  Achillion Completes Enrollment in Rare Blood Disorder Study Zacks
Mar-27-19 06:00AM  Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial GlobeNewswire
Mar-13-19 01:09PM  Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Are Analysts Right About The Drop In Earnings? Simply Wall St.
Mar-08-19 10:04AM  Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4 Zacks
06:00AM  Achillion to Present at the Barclays Global Healthcare Conference GlobeNewswire
Mar-07-19 06:00AM  Achillion Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-21-19 12:57PM  Why a Connecticut pharma firm moved its C-suite to Blue Bell American City Business Journals
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in Blue Bell, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FISHERMAN JASON SDirectorNov 14Option Exercise3.2820,00065,60090,000Nov 14 06:47 PM
Scheer DavidDirectorNov 13Option Exercise3.2820,00065,60040,000Nov 14 06:46 PM
Scheer DavidDirectorNov 13Sale6.3110,48566,19729,515Nov 14 06:46 PM
Truitt JosephChief Executive OfficerOct 16Option Exercise3.14133,484419,785136,984Oct 18 05:13 PM
Truitt JosephChief Executive OfficerOct 16Sale6.37133,484850,9473,500Oct 18 05:13 PM
Scheer DavidDirectorDec 14Option Exercise1.0520,00021,00020,000Dec 18 04:24 PM
VAN NOSTRAND ROBERT LDirectorDec 14Option Exercise1.0520,00021,00020,000Dec 18 04:22 PM